Description

Simple

Clinical

Overview

Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.

Pharmacology

Indication

Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).

Pharmacodynamic

Vatalanib is a novel oral angiogenesis inhibitor being developed by Schering (in collaboration with Novartis AG). Vatalanib selectively inhibits the tyrosine kinase domains of vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptor, and c-KIT.

Mechanism of action

Vatalanib potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis.

Absorption

Rapid onset of absorption

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Approximately 6 hours.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vatalanib
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
3,5-diiodothyropropionic acid
The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Vatalanib.
3,5-Diiodotyrosine
The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Vatalanib.
Abaloparatide
The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Vatalanib.
Acetaminophen
The serum concentration of Acetaminophen can be increased when it is combined with Vatalanib.
Benzylthiouracil
The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Vatalanib.
Carbimazole
The therapeutic efficacy of Carbimazole can be decreased when used in combination with Vatalanib.
Dibromotyrosine
The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Vatalanib.
Elcatonin
The therapeutic efficacy of Elcatonin can be decreased when used in combination with Vatalanib.
Follitropin
The therapeutic efficacy of Follitropin can be decreased when used in combination with Vatalanib.
Levothyroxine
The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Vatalanib.
Liothyronine
The therapeutic efficacy of Liothyronine can be decreased when used in combination with Vatalanib.
Liotrix
The therapeutic efficacy of Liotrix can be decreased when used in combination with Vatalanib.
Methimazole
The therapeutic efficacy of Methimazole can be decreased when used in combination with Vatalanib.
Methylthiouracil
The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Vatalanib.
Parathyroid hormone
The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Vatalanib.
Potassium Iodide
The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Vatalanib.
Potassium perchlorate
The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Vatalanib.
Propacetamol
The serum concentration of Propacetamol can be increased when it is combined with Vatalanib.
Propylthiouracil
The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Vatalanib.
Protirelin
The therapeutic efficacy of Protirelin can be decreased when used in combination with Vatalanib.
3 References
  1. 1 . Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M: Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. J Dermatol. 2007 Jul;34(7):419-29.PubMed: 17584317
  2. 2 . Lijnen HR, Van Hoef B, Kemp D, Collen D: Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. Biochim Biophys Acta. 2007 Sep;1770(9):1369-73. Epub 2007 Jun 15.PubMed: 17616257
  3. 3 . Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, Rottmann A, Denner K, Waldmeier F, Gross G, Masson E, Laurent D: Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos. 2006 Nov;34(11):1817-28. Epub 2006 Aug 1.PubMed: 16882767